Posted by Michael Wonder on 24 Feb 2022
Cystic fibrosis community disappointed with PTAC recommendations
23 February 2022 - New Zealand’s cystic fibrosis community received disappointing news today with a recommendation to PHARMAC that reduces the priority for funding Trikafta from high to medium for 12 and over, and the decision be deferred for those under the age of 12, pending the availability of further data.
Trikafta, the drug PHARMAC called “paradigm-shifting”, treats the cause for most people with cystic fibrosis.
